Physician profile
Billy J Hebert
NPI 1720446024
$8,442.27
in general payments reported to CMS, 2019-2025
32 companies · $3,221 in 2025
The $3,221 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $867 · 2022: $626 · 2023: $794 · 2024: $2,934 · 2025: $3,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256 · Travel and Lodging: $2,605 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.57 |
| Travel and Lodging | $2,604.79 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $4,110.35 | 2024-2025 | Indigo System, Ruby Coil, Penumbra System |
| Novartis Pharmaceuticals Corporation | $706.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $347.31 | 2021-2024 | Xarelto |
| Amgen INC. | $326.28 | 2021-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $323.54 | 2022-2025 | Assure Wcd |
| Boston Scientific Corporation | $302.79 | 2021-2025 | Wolverine Coronary Cutting Balloon, Eluvia, Synergy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.94 | 2021-2025 | Jardiance |
| Pfizer INC. | $201.66 | 2021-2025 | |
| Abbott Laboratories | $192.21 | 2021-2025 | Amplatzer Amulet |
| Abiomed | $191.36 | 2022-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $177.69 | 2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $171.80 | 2021-2025 | Lifevest |
| Esperion Therapeutics, INC. | $121.63 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $114.47 | 2023-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $110.54 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $105.93 | 2022-2023 | In.Pact Admiral |
| Merck Sharp & Dohme LLC | $87.20 | 2022-2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $84.00 | 2024-2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $71.56 | 2024-2025 | Onpattro |
| Scpharmaceuticals INC. | $65.23 | 2024-2025 | |
| Cardiva Medical, INC. | $61.32 | 2021-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Bard Peripheral Vascular, INC. | $40.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $36.45 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.99 | 2021-2023 | Livalo |
| Amarin Pharma, INC. | $30.30 | 2021-2022 | |
| Contego Medical, INC | $24.14 | 2025 | |
| Terumo Medical Corporation | $23.70 | 2023 | Heartrail |
| Sanofi-Aventis U.S. LLC | $23.60 | 2023 | |
| Atricure, INC. | $23.13 | 2023 | |
| Inari Medical, INC. | $19.98 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Acacia Pharma INC | $19.00 | 2021 | |
| Itamar Medical INC | $5.49 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.